A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 53-58

  Chi, K N ^a   Beardsley, E ^a   Eigl, B J ^b   Venner, P ^c   Hotte, S J ^d   Winquist, E ^e   Ko, Y J ^f   Sridhar, S S ^g   Weber, D ^h   Saad, F ⁱ  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c CROSS CANCER INSTITUTE   (Canada)

^d JURAVINSKI CANCER CENTRE   (Canada)

^e LONDON HEALTH SCIENCES CENTRE   (Canada)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^g PRINCESS MARGARET HOSPITAL   (Canada)

^h NOVARTIS PHARMA AG   (Switzerland)

ⁱ UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Patupilone; Phase II clinical trial; Prostate cancer

Indexed keywords

DOCETAXEL; EPOTHILONE B; NARCOTIC ANALGESIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DEHYDRATION; DIARRHEA; DIGOXIN BLOOD LEVEL; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; KIDNEY FAILURE; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PAIN ASSESSMENT; PALLIATIVE THERAPY; PARESTHESIA; PATIENT DECISION MAKING; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SURVIVAL TIME; TASTE DISORDER; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CANADA; CASTRATION; DISEASE-FREE SURVIVAL; EPOTHILONES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SALVAGE THERAPY; TAXOIDS;

EID: 82055202474     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr336     Document Type: Article

References (17)

1. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
3. O'Reilly T, McSheehy PM, Wenger F et al. Patupilone (epothilone B, EPO906) inhibits growth and metastasis of experimental prostate tumors in vivo. Prostate 2005; 65: 231-240.
4. ten Bokkel Huinink WW, Sufliarsky J, Smit WM et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 2009; 27: 3097-3103.
5. Rubin EH, Rothermel J, Tesfaye F et al. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors. J Clin Oncol 2005; 23: 9120-9129.
6. Hussain A, DiPaola RS, Baron AD et al. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009; 20: 492-497.
7. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
8. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
9. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
10. Benson AB III, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004; 22: 2918-2926.
11. Beer TM, Ryan CW, Venner PM et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008; 112: 326-330.
12. Jankovic B, Beardsley E, Chi KN. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysis. 2008 Genitourinary Cancers Symposium (Abstr 196). 2008.
13. Hussain M, Tangen CM, Lara PN Jr. et al. Ixabepilone (epothilone B analogue BMS-247550) is active in chemotherapy-naive patients with hormone-refractory prostate cancer: a Southwest Oncology Group trial S0111. J Clin Oncol 2005; 23: 8724-8729.
14. Rosenberg JE, Weinberg VK, Kelly WK et al. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007; 110: 556-563.
15. Graff J, Smith DC, Neerukonda L et al. Phase II study of sagopilone (ZK-EPO) plus prednisone as first-line chemotherapy in patients with metastatic androgenindependent prostate cancer (AIPC). J Clin Oncol 2008; 26 (Suppl): (Abstr 5141).
16. Beer TM, Higano CS, Saleh M et al. Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 2007; 25: 565-570.
17. deBono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-1154.